dc.contributor.author
Goldsobel, Gady
dc.contributor.author
Herrath, Christoph von
dc.contributor.author
Schlickeiser, Stephan
dc.contributor.author
Brindle, Nicola
dc.contributor.author
Stähler, Frauke
dc.contributor.author
Reinke, Petra
dc.contributor.author
Aberman, Zami
dc.contributor.author
Ofir, Racheli
dc.contributor.author
Dessole, Gabriella
dc.contributor.author
Benvenuti, Stefano
dc.contributor.author
Neves, Nuno M.
dc.contributor.author
Reis, Rui L.
dc.contributor.author
Moll, Guido
dc.contributor.author
Volk, Hans-Dieter
dc.date.accessioned
2022-01-21T09:52:34Z
dc.date.available
2022-01-21T09:52:34Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/33677
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-33397
dc.description.abstract
Advanced therapy medicinal products (ATMPs) are potential game changers in modern medical care with an anticipated major impact for patients and society. They are a new drug class often referred to as "living drugs," and are based on complex components such as vectors, cells and even tissues. The production of such ATMPs involves innovative biotechnological methods. In this survey, we have assessed the perception of European citizens regarding ATMPs and health care in Europe, in relation to other important topics, such as safety and security, data protection, climate friendly energy supply, migration, and others. A crucial question was to determine to what extent European citizens wish to support public funding of innovations in healthcare and reimbursement strategies for ATMPs. To answer this, we conducted an online survey in 13 European countries (representative of 85.3% of the entire EU population including the UK in 2020), surveying a total of 7,062 European citizens. The survey was representative with respect to adult age groups and gender in each country. Healthcare had the highest ranking among important societal topics. We found that 83% of the surveyed EU citizens were in support of more public funding of technologies in the field of ATMPs. Interestingly, 74% of respondents are in support of cross-border healthcare for patients with rare diseases to receive ATMP treatments and 61% support the reimbursement of very expensive ATMPs within the European health care system despite the current lack of long-term efficacy data. In conclusion, healthcare is a top ranking issue for European Citizens, who additionally support funding of new technologies to enable the wider application of ATMPs in Europe.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
advanced therapies
en
dc.subject
advanced therapy medicinal products (ATMPs)
en
dc.subject
European Union
en
dc.subject
survey in Europe
en
dc.subject
public perception
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europe — Why the European Union Should Invest More!
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
739987
dcterms.bibliographicCitation.doi
10.3389/fmed.2021.739987
dcterms.bibliographicCitation.journaltitle
Frontiers in Medicine
dcterms.bibliographicCitation.originalpublishername
Frontiers Media SA
dcterms.bibliographicCitation.volume
8
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
34765617
dcterms.isPartOf.eissn
2296-858X